73 related articles for article (PubMed ID: 33688919)
1. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.
Pach J; Olamiju B; Weiss S; Damsky W; Leventhal J
JAMA Dermatol; 2021 Apr; 157(4):468-469. PubMed ID: 33688919
[No Abstract] [Full Text] [Related]
2. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
Emile J; Cauquil C; Carpentier D; Routier E; Robert C
Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
[No Abstract] [Full Text] [Related]
3. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
Versluis JM; Reijers ILM; Rozeman EA; Menzies AM; van Akkooi ACJ; Wouters MW; Ch'ng S; Saw RPM; Scolyer RA; van de Wiel BA; Schilling B; Long GV; Blank CU
Eur J Cancer; 2021 May; 148():51-57. PubMed ID: 33735809
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Nishiyama T; Chen LT; Kang YK
Gastric Cancer; 2021 Jul; 24(4):946-958. PubMed ID: 33743112
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
6. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
[TBL] [Abstract][Full Text] [Related]
7. Incessant Atrial Tachycardia Following Combination Chemotherapy with Cetuximab, Cisplatin and 5-Fluorouracil for Hypopharyngeal Cancer.
Sahashi Y; Nawa T
Cardiovasc Toxicol; 2021 Jun; 21(6):494-497. PubMed ID: 33830451
[TBL] [Abstract][Full Text] [Related]
8. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Lei M; Siemers NO; Pandya D; Chang H; Sanchez T; Harbison C; Szabo PM; Janjigian Y; Ott PA; Sharma P; Bendell J; Evans TRJ; de Braud F; Chau I; Boyd Z
Clin Cancer Res; 2021 Jul; 27(14):3926-3935. PubMed ID: 33782030
[TBL] [Abstract][Full Text] [Related]
9. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP; de Joode K; Litière S; Ten Tije AJ; Suijkerbuijk KPM; Boers-Sonderen MJ; Hospers GAP; de Groot JWB; van den Eertwegh AJM; Aarts MJB; Piersma D; van Rijn RS; Kapiteijn E; Vreugdenhil G; van den Berkmortel FWPJ; Hoop EO; Franken MG; Ryll B; Rutkowski P; Sleijfer S; Haanen JBAG; van der Veldt AAM
BMC Cancer; 2021 Mar; 21(1):323. PubMed ID: 33765967
[TBL] [Abstract][Full Text] [Related]
10. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events after a single dose of pembrolizumab.
Vos H; Lambein K; Wildiers H; Punie K; Smeets A
Eur J Cancer; 2021 May; 148():92-94. PubMed ID: 33740501
[No Abstract] [Full Text] [Related]
13. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
14. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.
Reville PK; Kantarjian HM; Ravandi F; Jabbour E; DiNardo CD; Daver N; Pemmaraju N; Ohanian M; Alvarado Y; Xiao L; Alatrash G; Loghavi S; Rausch CR; Borthakur G; Konopleva M; Cortes J; Kadia TM
Blood Cancer J; 2021 Mar; 11(3):60. PubMed ID: 33731681
[No Abstract] [Full Text] [Related]
16. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
17. Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
Uhara H; Kiyohara Y; Uehara J; Fujisawa Y; Takenouchi T; Otsuka M; Uchi H; Fukushima S; Minami H; Hatsumichi M; Yamazaki N
J Dermatol; 2021 May; 48(5):592-599. PubMed ID: 33715172
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant ICI Response, Microbiome Probed in NSCLC.
Cancer Discov; 2021 May; 11(5):OF1. PubMed ID: 33712491
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.
Guida M; Strippoli S; Maule M; Quaglino P; Ramondetta A; Chiaron Sileni V; Antonini Cappellini G; Queirolo P; Ridolfi L; Del Vecchio M; Cocorocchio E; Di Giacomo AM; Festino L; Merelli B; Occelli M; Brugnara S; Minisini A; Sava S; Tommasi S; De Summa S;
ESMO Open; 2021 Apr; 6(2):100064. PubMed ID: 33711672
[TBL] [Abstract][Full Text] [Related]
20. Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience.
Al Jarroudi O; Chaabouni H; Ulusakarya A; Almohamad W; Gumus Y; Goldschmidt E; Afqir S; Morère JF
Clin Case Rep; 2021 Apr; 9(4):2162-2167. PubMed ID: 33936657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
